Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Jade Biosciences, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Jade Biosciences, Inc. (JBIO $14.05), a clinical-stage biotechnology company focused on developing novel biologics for the treatment of autoimmune diseases.

    Read more

  • Q&A With William Blair’s Myles Minter, Named a TipRanks Top 10 Analyst of 2025

    Recently ranked 4th in TipRank's top 10 list of U.S. analysts, Minter reflects on biotech’s inflection point, the themes that defined 2025, and the disciplined framework that guides his approach.

    Read more

  • Economics Weekly: Iran, Energy, and the New Rules of Global Power

    In this Economics Weekly, Richard de Chazal attempts to lay out our view of the conflict, how this fits into the global geopolitical framework, and what this might mean for financial markets.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures